European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- ((new)) < 5000+ AUTHENTIC >

| Parameter | Ph. Eur. 0478 | USP <701>/<711> | JP (General Tests) | | :--- | :--- | :--- | :--- | | Disintegration time (uncoated) | 15 min | 15 min (but often 30 min for large tabs) | 15 min | | Dissolution vessel volume | 900 mL (preferred) | 500, 900, or 1000 mL | 900 mL | | Friability acceptance | 1.0% (uncoated) | 1.0% (but 0.8% for high-use) | 1.0% | | Uniformity of dosage units | AV ≤ 15.0 (2.9.40) | AV ≤ 15.0 (identical via ICH Q4B) | AV ≤ 15.0 |

In the landscape of pharmaceutical quality control, few documents carry as much authoritative weight as the monographs of the European Pharmacopoeia (Ph. Eur.) . For manufacturers seeking to market oral solid dosage forms within the 38 member states of the European Pharmacopoeia Convention (and beyond, via the CE marking or WHO prequalification), compliance is non-negotiable. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

At the heart of oral solid dosage regulation lies . While it may seem like a generic entry, Monograph 0478 is the foundational legal text defining what a tablet is, how it must behave, and the tests it must pass before it is deemed safe for human use. Unlike active substance monographs (e.g., Paracetamol or Aspirin), this is a general monograph . It applies to all tablet formulations unless specifically waived or modified by an individual product monograph. | Parameter | Ph